- In May 2025, the Financial Times reported that Xellia Pharmaceuticals, Europe's last manufacturer of key antibiotic ingredients, announced the closure of its largest domestic factory in Copenhagen and the relocation of production to China due to unsustainable competition. This decision is expected to result in 500 job losses
- In March 2025, Reuters reported that the European Commission proposed the Critical Medicines Act, aiming to reduce reliance on Asia for antibiotics and other critical drugs. This initiative seeks to secure the supply of 270 medicines identified as critical for health security in the EU
- In August 2024, a study published on arXiv discussed advancements in drug delivery systems for macrolide antibiotics. The research focused on programmable lipid nanoparticles, which are expected to improve the efficacy, patient compliance, and therapeutic outcomes of treatments
- In February 2024, the U.S. Food and Drug Administration (FDA) approved a new macrolide antibiotic, Solithromycin, for the treatment of community-acquired bacterial pneumonia (CABP). This approval provides an alternative for patients with macrolide-resistant infections
- In April 2022, Teva Pharmaceutical Industries Ltd. expanded its line of economical treatment alternatives for bacterial infections by launching a generic version of the popular macrolide antibiotic clarithromycin. This action supports Teva's objective to address the growing need for effective antibiotics while guaranteeing their accessibility and affordability for patients everywhere, hence fostering the company's expansion in the global market for macrolide antibiotics
